Abivax S.A.
Clinical trials sponsored by Abivax S.A., explained in plain language.
Biotech developing treatments for inflammatory diseases and viral infections.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers needed to Taste-Test a new drug pill Results expected Sep 2026 (estimated)
- New pill could tame Crohn's Flare-Ups Results expected Dec 2026 (estimated) May already have reported ↗
-
New pill hopes to stop UC Flare-Ups in their tracks
Disease control OngoingThis phase 3 trial tests whether a daily pill called ABX464 (obefazimod) can help people with moderate-to-severe ulcerative colitis stay in remission. Over 1,100 participants who completed an earlier induction study will receive either 25 mg, 50 mg, or a placebo for 44 weeks. The…
Phase 3 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New pill shows promise for Long-Term ulcerative colitis control
Disease control OngoingThis study tests the long-term safety and effectiveness of an experimental drug called ABX464 in people with moderate to severe ulcerative colitis. Participants who previously improved on ABX464 in earlier studies will continue taking it daily for up to 54 months. Researchers wil…
Phase 2 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC